What's in a Mounjaro Injection — and How Does It Work?

You're holding the pen, here's what's actually in it

Picture yourself pulling a Mounjaro KwikPen from the fridge, turning it in your hand before your weekly Mounjaro injection. The liquid inside is a clear, colourless solution. The active ingredient is tirzepatide, a 39-amino-acid synthetic peptide engineered to bind to both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. No other weight-management medicine licensed in the UK does both.

The inactive excipients (the ingredients that carry and stabilise tirzepatide) include sodium phosphate (a buffer that keeps the pH stable), sodium chloride (to make the solution compatible with body fluids), hydrochloric acid or sodium hydroxide to adjust pH, and water for injections. None of these excipients have pharmacological activity; their job is to keep tirzepatide stable until it reaches your tissue. You can read the full list in the Mounjaro Summary of Product Characteristics on the eMC, which is the definitive reference our prescribers and pharmacists consult for formulation detail.

One practical check worth doing every week: hold the pen up to the light before injecting. The solution should be clear and free of particles. If it looks cloudy or discoloured, do not use that pen, contact your prescriber or pharmacy. Takes about three seconds and matters.

The pen itself contains four weekly doses in one cartridge. When you press the button, a very fine needle delivers the subcutaneous dose automatically at the pre-set volume. More on how the pen mechanism works is covered on the Mounjaro KwikPen guide.

How tirzepatide acts once it's under the skin

After injection, tirzepatide is absorbed into the bloodstream and begins binding to GIP and GLP-1 receptors in the gut, pancreas and brain. GLP-1 receptor activation (which semaglutide also produces) slows how quickly food leaves the stomach, prompts the pancreas to release insulin in response to rising blood sugar, and signals fullness to the brain. GIP receptor activation adds a second appetite-reducing pathway and appears to enhance the overall effect on energy intake. The two pathways together are why tirzepatide's trial results sit where they do.

In the SURMOUNT-1 trial, involving more than 2,500 adults with obesity or overweight and at least one weight-related condition but without type 2 diabetes, participants on 15 mg tirzepatide achieved an average body-weight reduction of around 20–21% over 72 weeks, results that informed NICE's recommendation of tirzepatide in Technology Appraisal 1026. The SURMOUNT programme as a whole covered more than 10,000 participants across obesity and diabetes trials combined.

None of this happens instantly. The titration schedule (starting at 2.5 mg and stepping up, typically in four-week intervals under prescriber guidance) allows your system to adapt before the dose increases. The fuller explanation of what Mounjaro is and how it is approved covers the mechanism and licensing in more depth if you want to read further.

Injection sites, storage and why the formulation is temperature-sensitive

Tirzepatide in solution is a peptide, and peptides degrade. That is why the KwikPen must be stored in a refrigerator at 2–8 °C until you use it. There is a limited window during which it can be kept at room temperature, the exact window is stated in the Patient Information Leaflet that comes with your pen, and the NHS tirzepatide page also summarises storage requirements clearly. Do not freeze it; freezing damages the solution.

Approved injection sites are the abdomen, outer thigh and upper arm. Rotating the site each week matters: repeated injections at the same spot can cause the tissue to thicken, which alters how consistently tirzepatide is absorbed. More detail on technique and site rotation is on the injection site guide. After each injection, the used pen goes into a sharps container rather than your household bin, a 1-litre sharps container is available from our pharmacy if you need one.

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber weighs the full clinical picture, BMI alone never determines suitability. Our Mounjaro overview sets out the eligibility criteria in plain terms.

What this means if you're considering treatment

Understanding the ingredients and mechanism isn't just curiosity. It helps you recognise what a genuine, pharmacy-dispensed pen should look like, store correctly, and have realistic expectations about timelines. The 2.5 mg starting dose will not feel dramatic, it is not meant to. Your body is adjusting to a molecule it has never encountered. The therapeutic work happens as the dose steps up under clinical supervision.

Private treatment through a regulated online pharmacy means no referral, no waiting list, but it does mean a clinical assessment first. Our prescribers review every consultation personally before anything is approved or dispatched. If you'd like to understand the costs involved before you decide, the Mounjaro cost page explains what private treatment typically includes and how pricing is structured in the UK. And if you have questions about how our service works, the about us page covers our pharmacy registration and clinical team. When you're ready to take the next step, start your free consultation and a GPhC-registered prescriber will review your answers the same day.